Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.